We are pleased to announce that the preclinical business of SNBL USA will be transferred to Altasciences. The transaction is expected to be finalized at the end of September.
SNBL USA’s extensive experience in preclinical safety assessment and Altasciences’ vast experience in early phase clinical trials, as well as our combined bioanalytical capabilities creates an unparalleled structure that will offer a wide array of solutions to seamlessly and efficiently progress from preclinical through early phase clinical testing, for both small and large molecules.
“Altasciences’ strong core values, commitment to excellent customer service and high-quality science made this restructuring the ideal fit for SNBL. SNBL Group will continue to provide comprehensive, preclinical services at our sites in Japan.” said SNBL Group CEO Dr. Ryoichi Nagata.